US5089181A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of dehydrating vesicle preparations for long term storage
Assignee: Nexstar Pharmaceuticals Inc
•
Filing: 1989-10-30
•
Granted: 1992-02-18
•
Expires: 2009-10-30
Abstract
Abstract In the presence of a preserving additive, unilamellar phospholipid vesicle preparations are preserved during dehydration. Dehydration is effected by subjecting said preparations to a drying operations capable of causing flash evaporation.
Inventors
- 👤 Helmut O. Hauser
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 09:24
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; Y; Y10; Y10S; Y10S436/00; Y10S436/829
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
52 words
A method of dehydrating a liposome preparation, comprising spray drying liposomes suspended in an aqueous dispersion medium in the presence of a preserving additive at a temperature of 60° C. to 150° C., to produce a liposome preparation, which when reconstituted, maintains substantially the size, size distribution and integrity of the liposomes.
Claim 2
Independent Claim
52 words
A method of dehydrating a liposome preparation, comprising spray drying liposomes suspended in an aqueous dispersion medium in the presence of a preserving additive at a temperature of 60° C. to 150° C., to produce a liposome preparation, which when reconstituted, maintains substantially the size, size distribution and integrity of the liposomes.
Claim 3
Dependent Claim
15 words
The method according to claim 1 wherein the liposomes are less than about 2000 A.
Claim 4
Dependent Claim
11 words
The method according to claim 1 wherein the liposomes are unilamellar.
Claim 5
Dependent Claim
20 words
The method according to claim 1 wherein the liposomes comprise phospholipids selected from the group consisting of phosphatidylcholines and phosphatidylserines.
Claim 6
Dependent Claim
17 words
The method according to claim 4 wherein said phosphatidylcholines are egg phosphatidylcholine, 1-palmitoyl-2-oleoyl-sn-phosphatidylcholine, 1,2-palmitoyl-sn-phosphatidylcholine and 1,2 dioleoyl-sn-phosphatidylcholine.
Claim 7
Dependent Claim
17 words
The method according to claim 4 wherein said phosphatidylserines are dioleoyl-sn-phosphatidylserine, 1,2 dioleoyl-sn-glycero-3-phospho-L-serine, and ox brain phosphatidylserine.
Claim 8
Dependent Claim
23 words
The method according to claim 1 wherein said preserving additive is selected from the group consisting of carbohydrates, alcohols, proteins and gum arabic.
Claim 9
Dependent Claim
16 words
The method according to claim 7 wherein said carbohydrate is dextran, a monosaccharide or a disaccharide.
Claim 10
Dependent Claim
20 words
The method according to claim 8 wherein said disaccharides are selected from the group consisting of sucrose, lactose and trehalose.
Claim 11
Dependent Claim
11 words
The method according to claim 8 wherein said monosaccharide is glucose.
Claim 12
Dependent Claim
12 words
The method according to claim 7 wherein said preserving additive is sucrose.
Claim 13
Dependent Claim
21 words
The method according to claim 11 wherein said sucrose is present in an amount from about 5% to about 10% sucrose.
Claim 14
Dependent Claim
21 words
The method according to claim 7 wherein said alcohols are selected from the group consisting of glycerol, mannitol and ethylene glycol.
Claim 15
Dependent Claim
15 words
The method according to claim 7 wherein said preserving additive is albumin or gum arabic.
Claim 16
Dependent Claim
14 words
The method according to claim 1 wherein the liposomes include therapeutic and/or diagnostic agents.
Claim 17
Dependent Claim
26 words
The method according to claim 15 wherein said therapeutic agents are selected from the group consisting of antibiotics, metabolic regulators, immune modulators, chemotherapeutics, and toxin antidotes.
Claim 18
Dependent Claim
24 words
The method according to claim 1 wherein the liposomes are subsequently reconstituted in an aqueous solution and upon reconstitution include therapeutic and/or diagnostic agents.
References Cited (Backward Citations)
US4370349A
Cited
US4229360A
Cited
US4229360B1
Cited
US4275088A
Cited
JPS55122095A
Cited
JPS5746921A
Cited
US4508703A
Cited
US4515736A
Cited
EP0140085A2
Cited
US4830858A
Cited
US4895719A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-17 | 1995-08-19 | 1996-02-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-17 | 1999-08-19 | 2000-02-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-17 | 2003-08-19 | 2004-02-18 | $7700.00 | Window Closed / Lapsed |